The issue is credibility and financing of these projects. With very little money in the bank and the risk of further dilution if it taps LPC money, the stock will go no where until either a BP steps up or revenues start to flow from Lympro. It appears that Gerald is betting on revs than relying on a deal with BP unless that deal is advantageous and doesn't make AMBS overly reliant on the BP. We will see how this unfolds.